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Abstract
The effects of erythropoietin administration on mitral regurgitation in patients with congestive heart failure have not yet been examined.
After 2 months, erythropoietin treatment results in a significant reduction in left ventricular volumes and mitral regurgitation severity and
improves hemodynamics.
© 2008 Elsevier Ireland Ltd. All rights reserved.
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Anemia and mitral regurgitation (MR) are frequent in
patients with congestive heart failure (CHF) [1]. Both promote
left ventricular (LV) remodelling resulting in an increased
morbidity and mortality [2]. The effects of erythropoietin
(EPO) on left ventricular (LV) remodeling, MR, and indices of
LV filling pressure have not yet been examined. We
prospectively included 28 consecutive outpatients presenting
with severe CHF due to systolic LV dysfunction (ejection
fractionb45%), anemia (hemoglobinb12 g/dl), and chronic
renal failure (creatinine clearanceb45 ml/min). All were in a
pre-dialysis condition. Fourteen of them were randomly
assigned to receive EPO therapy and the remaining 14 served
as control patients. Echocardiography was performed at
baseline and after 2 months of treatment. Age, gender, medical
history and treatment regimen were distributed similarly in
both groups. After 2 months of EPO treatment, the New York
Heart Association class improved (2.2±0.5 vs 3.4±0.5,
pb0.01) whereas no significant change was observed in the
control group. The hemoglobin level (13.1±0.4 vs 10.1±
0.3 g/dl, pb0.001) as well as the systolic blood pressure
also increased in the treated group. The EPO treatment was
accompanied by a significant decrease in LVend-diastolic and
end-systolic volumes, in ERO— degree of MR—, and in
E/Em whereas LV ejection fraction and the LV systolic
performance as estimated by LV dP / d t improved
(pb0.001). The LV function, LV volumes, and MR degree
remained fairly unchanged in the control group. At baseline,
higher LV volumes, larger mitral annular areas and greater
apical displacement of posterior papillary muscle (r=0.67,
p=0.0037) were associated with higher ERO. Mitral
deformation increased significantly with higher degree of
MR. LV dP / dt was not related to ERO. EPO-induced
changes in MR were unrelated to changes in LV volumes
whereas they were correlated with changes in systolic blood
pressure, in valvular deformation and in regional LV
remodeling. The strongest correlations with ERO changes
were observed with the differences in apical displacement of
posterior papillary muscle, in LV dP / dt and in coaptation
height. Using multivariate analysis, a decrease in the apical
displacement of posterior papillary muscle (p=0.0004) and
the rise in LV dP / dt (p=0.001) emerged as independent
cofactors associated with EPO-induced MR reduction
(R2 =0.91). To note, the decrease in LV filling pressure—
E/Em— was correlated with changes in ERO and with the
decrease in transtricuspid pressure gradient.
Anemia, increased LV filling pressure, LV remodeling
and MR are frequent in CHF patients [1]. All of these
features are independently predictive of adverse outcome.
The present study shows that treating anemia by EPO in
CHF results in a significant reduction in LV volumes and
MR severity and improves hemodynamics. Decrease in MR
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degree is interrelated to changes in regional LV remodeling
and is directly correlated to the improvement in LV systolic
performance. MR improvement is accompanied by both a
decrease in E/Em ratio — a non-invasive estimate of LV
filling pressure— and in pulmonary pressure.
The present study confirms and extends the results of
previous reports showing that EPO administration
improves clinical status and hemodynamics and is
accompanied by progressive reverse LV remodeling [3,4].
As a result, the LV ejection fraction increases and the LV
systolic performance— LV dP / dt— rises. Concomitantly,
the tension applied on mitral valve decreases — reverse
regional LV remodeling (slighter apical displacement of
mitral leaflets). The balance of forces acting on mitral
leaflets is thus improved resulting in a significant decrease
in MR severity. Under basal conditions, regurgitant volume
is also determined by the systolic pressure gradient across
the orifice [5]. Transmitral pressure, which drives regur-
gitant flow, also promotes valve closure. Therefore, the rise
in systemic blood pressure observed in the EPO group
could also reduce MR by increasing closing force.
Obviously, this positive effect is only possible if tethering
decreased. Transmitral pressure can also be increased by
decreasing atrial pressure which reflects the level of LV
end-diastolic pressure. In this study, we showed that LV
filling pressure as estimated by E/Em was lower after EPO
treatment. Such a reduction reflects the decrease in MR
degree and better LV diastolic function.
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